Yoshitsugu Kojima

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Topics

Chronic Kidney Disease

Major Depressive Disorder

Ejection Fraction

Top Venues

Neuropsychopharmacology reports

PharmacoEconomics

This page only lists publications with an associated author ORCID identifier.

Publications

Kazuyuki Nakagome, Hisateru Tachimori, Shiro Endo, Ken Murakami, Takaharu Azekawa, Seiji Hongo, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamada, Hideki Oi, Tomiki Sumiyoshi
A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder. Neuropsychopharmacology reports 44 (1) (2024)
Takao Takeshima, Fumihiko Sakai, Xinyu Wang, Kentaro Yamato, Yoshitsugu Kojima, Yilong Zhang, Craig Bennison, Martijn J H G Simons
Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective. PharmacoEconomics (2024)
Kazuyuki Nakagome, Hisateru Tachimori, Shiro Endo, Ken Murakami, Takaharu Azekawa, Seiji Hongo, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamada, Hideki Oi, Tomiki Sumiyoshi
A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder. Neuropsychopharmacology reports 44 (1) (2024)
Takao Takeshima, Fumihiko Sakai, Xinyu Wang, Kentaro Yamato, Yoshitsugu Kojima, Yilong Zhang, Craig Bennison, Martijn J H G Simons
Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective. PharmacoEconomics 42 (7) (2024)
Kazuyuki Nakagome, Hisateru Tachimori, Shiro Endo, Ken Murakami, Takaharu Azekawa, Seiji Hongo, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamada, Hideki Oi, Tomiki Sumiyoshi
A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder. Neuropsychopharmacology reports 44 (1) (2024)
Kazuyuki Nakagome, Hisateru Tachimori, Shiro Endo, Ken Murakami, Takaharu Azekawa, Seiji Hongo, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamada, Hideki Oi, Tomiki Sumiyoshi
A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder. Neuropsychopharmacology reports (2024)
Takao Takeshima, Fumihiko Sakai, Xinyu Wang, Kentaro Yamato, Yoshitsugu Kojima, Yilong Zhang, Craig Bennison, Martijn J H G Simons
Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective. PharmacoEconomics 42 (7) (2024)
Kazuyuki Nakagome, Hisateru Tachimori, Shiro Endo, Ken Murakami, Takaharu Azekawa, Seiji Hongo, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamada, Hideki Oi, Tomiki Sumiyoshi
A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder. Neuropsychopharmacology reports 44 (1) (2024)
Takao Takeshima, Fumihiko Sakai, Xinyu Wang, Kentaro Yamato, Yoshitsugu Kojima, Yilong Zhang, Craig Bennison, Martijn J H G Simons
Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective. PharmacoEconomics 42 (7) (2024)
Jun Ishigooka, Tomohiro Usami, Shuichi Iwashita, Yoshitsugu Kojima, Satoshi Matsuo
Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study (Secondary Publication). Neuropsychopharmacology reports 40 (2) (2020)